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Prognostic significance of p53-expression in colorectal
carcinomaasmeasuredbyaluminometricimmunoassay
Die Untersuchung der luminometrisch bestimmten p53-Expression auf
deren prognostischen Wert beim kolorektalen Karzinom
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Background: Mutations of the TP53 gene induce the production of ab-
normal p53-protein with a prolonged half-life allowing its detection by
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immunoassay did not correlate with various clinicopathological param-
eters. Follow-up ranged from 2.4 to 54.3 (mean 25.3) months. During
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Conclusion: Our investigation revealed that p53-overexpression as
measured by a luminometric immunoassay, is not a useful predictor of
prognosis in patients with colorectal adenocarcinoma. Overcoming the
limit of semiquantitative immunohistochemistry for p53-protein quan-
titative immunoluminometry may be useful elucidating the relation
between serum p53-antibodies and p53 in cytosols.
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Zusammenfassung
Einleitung:MutationenimTP53-GenführenzurExpressioneinesabnor-
malen p53-Proteins mit verlängerter Halbwertszeit. Dieses kann durch
monoklonale Antikörper nachgewisesn werden. In der vorliegenden Ar-
beit wurde unter Anwendung eines neuen Lumineszenz-Immunoassay
(LIA) untersucht, ob eine erhöhte p53-Expression beim kolorektalen
KarzinommiteinerschlechterenPrognosederBetroffeneneinhergeht.
Methoden:Zytoplasmatischesp53wurdein144Kolon-undRektumma-
lignomen und 96 Proben normaler Mukosa unter Verwendung eines
quantitativen Lumineszenz-Immunoassay bestimmt.
Ergebnisse: Bei 112 Proben (77,8%) wurde eine p53-Konzentration
nachgewiesen, die größer als der Cut-off-Wert von 0,15 ng p53 pro mg
Gesamtproteinwar.DasErgebnisimLumineszenz-Immunoassaykorre-
lierte nicht mit verschiedenen klinisch-pathologischen Parametern.
Während des medianen Beobachtungszeitraumes von 25,3 Monaten
(Bereich 2,4–54,3 Monate) entwickelten 61 Patienten ein Rezidiv, was
in 39 Fällen zum Tode führte.
Weder die univariate noch die multivariate Analyse der klinischen und
pathologischen Variablen sowohl bezüglich der rezidivfreien Periode
als auch des Gesamtüberlebens zeigten einen statistisch signifikanten
Unterschied zwischen hoher und niedriger p53-Expression.
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Research Article OPEN ACCESSSchlussfolgerung: Die luminometrisch bestimmte quantitative p53-Ex-
pression scheint kein Prognosefaktor für das Überleben bei Patienten
mitkolorektalemKarzinomzusein.JedochbietetdieMethodedeutliche
Vorteile gegenüber der semiquantitativen Immunhistochemie und
könnte insbesondere zur Klärung des Verhältnisses zwischen p53-Se-
rumantikörpern und p53-Protein im Zytosol beisteuern.
Schlüsselwörter: p53-Protein, kolorektales Karzinom, Prognose,
Tumormarker
Introduction
Colorectal cancer is the second leading cause of tumor
related death in Western countries. Recurrences occur
in 30–50% at which intensive follow-up could not show
any significant improvement in the last decades [1]. A
big problem of early diagnosis is the fact that many pa-
tients are asymptomatic for a long time [2]. There is dis-
cussion about how far follow-up has influence upon the
resultsaltogetherandtheindividualcourse.Tumorgrowth
in colorectal carcinoma is relatively slow, therefore good
chances for successul therapy of recurrence is given. On
the other hand, immense diagnostic effort is required to
discover the relapse in a curable stage.
In 1979 a new phosphoprotein named p53, which is
located on the short arm of human chromosome 17, was
discovered [3]. Nowadays, this alteration accounts for
the most common genetic abnormality in solid human
malignancies. Mutations in the p53-gene are present in
70–90% of colorectal carcinoma and they are thought to
bealateeventinthemultistepprogressoftumorigenesis
[4]. Wildtype-p53-protein plays an important role in cell-
cycleregulationbyarrestingcellswithmutagenicdamage
inlateG1phasebeforeenteringtheS-phase,thusacting
as a tumor-suppressor gene [5]. Mutant-p53 usually
undergoes conformational changes that prolong the
wildtype’s very short half-life of a few minutes to several
hours,leadingtointracellularaccumulation[6].Thus,the
mutant form not only loses suppressor activity but can
even promote tumor growth [7].
In solid neoplasms including carcinomas of the lung [8],
ovaries[9],pancreas[10],stomach[11]andthyroidgland
[12], immunohistochemically detected p53-expression
has been correlated with an unfavourable prognosis. So
far two publications have reported about a shortened
disease-free and overall survival in mammary carcinoma
using a modern immunoluminometric assay [13], [14].
By contrast, Daifard could find no correlation between
p53-overexpression and poor prognosis in breast car-
cinoma[15].FurthermoreFerrerostatedthattheprognos-
tic power of p53 is no higher than the well-recognized
prognostic parameters in node-negative breast cancer
[16].However,thisrelationshiphasnotbeenconsistently
observed in colorectal tumor and reports of different
groups are contradictory [17], [18].
In the present study, we applied a luminometric assay
(LIA) to quantify p53-protein in the cytosol of 144
colorectalcarcinomasand96referencetissuesofnormal
colorectalmucosa.Thefindingswerecorrelatedtoseveral
clinicopathological parameters. Our aim was to compare
p53-concentration with patients’ outcome in terms of
disease-free and overall survival in order to assess the
protein’s value as a prognostic factor.
Methods
Patients
Representative tissue samples of 144 patients who
underwent surgical treatment for primary sporadic
colorectalcancerwerecollected.Nopatienthadreceived
preoperative chemotherapy or radiotherapy. The speci-
mens were snap frozen in liquid nitrogen and stored at
–80°Cuntilexaminationinlaboratory.Sevencarcinomas
were located in the cecum, 15 in the ascending colon or
hepatic flexure, 6 in the transverse colon or splenic flex-
ure, 6 in the descending colon, 29 in the sigmoid colon
and 78 in the rectum. In addition, 3 synchronous tumors
werefound.ThedistributionaccordingtoUICCclassifica-
tion was: 35 cases Stage I (T1-2N0M0), 32 Stage II (T3-
4N0M0), 41 Stage III (T1-4N1-2M0) and 36 Stage IV (T1-
4N1-2M1). Histologically 3 tumors were well (G I), 119
moderately (G II) and 22 poorly (G III) differentiated.
Tumor size and preoperatively detected tumor markers
CEA and CA 19-9 were also recorded. Our collective con-
tained 59 female and 85 male patients treated due to
colorectal malignoma. The age ranged from a minimum
of 26 to a maximum of 89 years (median 61 years).
Follow-up ranged between 2.4 to 54.3 months (median
25.3 months).
Luminometric immunoassay (LIA)
Cytosolic p53-protein levels were determined applying a
quantitative sandwich-type luminometric assay [13].
LIA-mat
® p53 (Sangtec Medical, Bromma, Sweden) is a
monoclonaltwo-siteimmunoassaywithmonoclonalanti-
body 1801 coated polysterene tubes serving as solid
phase.First,100μlofeitherthepreparedsampleorp53-
standard and the same amount of a tracer solution con-
sistingofanaminobutylethylisoluminol(ABEI)-conjugated
DO1 monoclonal antibody were pipetted into the tubes
and incubated for 20 hours at room temperature. The
antibodies bind to different denaturation-resistant epi-
topes at the N-terminus of mutant and wild-type p53-
protein whereby luminescence-labelled antibody DO1 is
indirectly bound to the tube. Non-reacted anti-p53 was
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Tracer-p53 complex bound to the tube wall was sub-
sequently detected by a light reaction applying LIA-mat
®
service kit (Byk-Sangtec Diagnostica, Dietzenbach, Ger-
many).UsingLIA-matS300Analysator
®(Stratec,Dietzen-
bach, Germany) oxidation of isoluminol and thereby
emission of photons was started by the automatic injec-
tion of alkaline peroxide solution and catalyst solution
into the test tubes. Given that this emission vanishes
within short time (less than 20 seconds) a luminometer
isrequiredtocatchthesignalsat425nm.Thelightsignal
measured in RLUs (relative light units) by a photomulti-
plier is directly proportional to the amount of existent
p53.Acalibrationcurveallowsrenderingthephosphopro-
tein’s content in ng p53 per mg total protein.
Determination of the cut-off value
To differentiate between tissues with elevated levels of
thephosphoroteinandthosewithnormalp53-expression,
we looked for a value in the group of healthy colorectal
reference mucosa, at which 95% of data were lower and
only 5% higher than this figure. By doing so we found a
cut-off value of 0.15 ng per mg for p53-concentration.
Statistical analysis
The relation of luminometric p53-expression to various
clinicopathological parameters was evaluated using
Wilcoxon's rank sum test for two group comparisons and
the Kruskal-Wallis test for comparisons of more than two
groups of categorized variables. Spearman rank corre-
lations were performed when variables were continous.
Theperiodfromthedateofresectiontothedateofdeath
or last observation (if alive) was used for prognostic
evaluation. The log-rank test was applied to compare
Kaplan-Meier survival curves. In addition, Cox's propor-
tional hazards model was performed with backward
elimination for selection of prognostic factors using a
significance level of 0.05.
Results
The assay was performed on cytosolic preparations of
144 primary colorectal adenocarcinomas with p53-pro-
tein-concentrationsrangingfrom0.004ng/mgto16.719
ng/mg (median 0.530 ng/mg). Setting the cut-off value
at 0.15 ng/mg, 112 soluble fractions (77.8%) showed
overexpression of the phosphoprotein. Besides, to com-
pare these values with a reference and to determine an
adequate cut-off point we analysed 96 specimens of
normal colorectal mucosa (range 0.028–0.048 ng/mg,
median 0.039 ng/mg) with the median value approxi-
mately 14 times lower than in malignant neoplasia.
The relationship between p53 expression and several
clinicopathological variables was examined and no
correlation could be found with tumor stage, histological
grade, tumor diameter or localisation, age, sex or the
tumor markers CEA and CA 19-9 (Table 1).
Follow-up ranged from 2.4 to 54.3 months (median 25.3
months) with survey of our collective in 15.3% less than
one year, 31.9% between one and two years and 52.8%
more than two years. Out of 144 patients 62 developed
recurrence(43.1%),and39diedoftheunderlyingdisease
(27.1%). Five deaths were not tumor-related. Within the
first postoperative year 58.1% of the recurrences oc-
curred, increasing to 93.5% after 2 years. Recurrences
were located in the liver (55.7%), lung (4.9%), abdominal
wall, peritoneum, lymph nodes and in 34.4% several
organs were affected.
Forty-nine out of 112 patients with p53-positive carcin-
omas (43.8%) developed recurrences, in comparison to
the 13 out of 32 affected patients with negative protein
expression (40.6%). The overall survival was 31 (29.0%)
and 8 (25.0%), respectively. The 2-year relapse-free sur-
vival rate was 58.6% in the group of high p53-concentra-
tion compared to 63.6% in p53-negative lesions. The
overallsurvivalamounted73.6%and87.9%,respectively.
After only 7.7 months a quarter of the first group had re-
currences compared to 17.0 months in the latter
(p=0.43). For overall survival the first quartiles were at
17.5 months and 32.1 months, respectively (p=0.24).
Kaplan-Meier survival curves are shown in Figure 1 and
Figure 2.
Althoughlowp53-expressionhadaslightlybetterprogno-
sis in terms of disease-free survival and overall survival,
the log-rank test did not show statistical significance.
Whensplitintoitssinglecategories,advancedTNM-stage
wasassociatedwithworseprognosis.Thesamewastrue
forCA19-9.Gradingandpatient'sageshowedsignificant
differencesinoverall-survivalandhighlevelsofCEAwere
related to shortened relapse-free survival (Table 2).
In addition, multiple Cox regression was performed to
assess the influence of risk-factors on recurrence-free
and overall survival (Table 3).
Only two factors were shown to have an effect on progno-
sis:PatientsinDukesstageIV(Dukesclassification)were
at higher risk for relapse by a factor of 6, and the risk for
tumor-related death was seven times higher compared
to Dukes stage I. Moreover, patients presenting CA 19-9
levels exceeding 37 U/l had a risk of recurrence or death
that was approximately twice as high compared to tumor
marker negative patients. There was no statistically sig-
nificant survival advantage for patients with low p53-ex-
pression.
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Lotter et al.: Prognostic significance of p53-expression in colorectal ...Figure 1: Relapse-free survival of patients whose tumors expressed p53-protein in a concentration higher than 0.15 ng/mg
(solid curve) compared to low p53-expression (hatched curve)
Figure 2: Overall survival of patients whose tumors expressed p53-protein in a concentration higher than 0.15 ng/mg (solid
curve) compared to low p53-expression (hatched curve)
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Lotter et al.: Prognostic significance of p53-expression in colorectal ...Table 2: Recurrence-free and overall survival in months related to different clinicopathological parameters (25%-rf = a quarter
of the patients were free of recurrences after the observation period, 25%-os = a quarter of the patients were still alive after
the observation period, n.r. = value not reached)
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analysis
Discussion
In the present study, p53-expression in 144 colorectal
adenocarcinomaswasmeasuredbyaquantitativelumino-
metricimmunoassayandrelatedtovariousclinicopatho-
logical parameters and prognosis, with the emphasis on
examiningthephosphoprotein'spotentialroleasaninde-
pendent prognostic factor. We used monoclonal antibod-
ies DO1 and PAb 1801, both of which are able to recog-
nize not only the mutant forms, but also wildtype-p53
protein at denaturation resistant epitopes at the N-ter-
minus of the molecule [19].
Using a cut-off value of 0.15 ng p53 per mg total protein,
determined by the analysis of 96 normal tissue speci-
mens,immunoluminometricallydetectedp53-overexpres-
sion was observed in 77.8%, which is comparable to
resultsinimmunohistochemistry[20],[21].Ourreference
samples showed a median value of 0.039 ng/mg, which
is almost 14 times lower than the correspondent value
of the tumor group (median 0.530 ng/mg). Borg et al.
[13] and de Witte et al. [14], who applied a similar im-
munoluminometric assy to breast carcinoma, found high
levelsofTP53proteinin30%and28%oftheirspecimen,
respectively, using cut-off points at the same level as we
did in the first study and 2.5 ng/mg in the latter. The
correspondence of our value with the one in the study of
Borg et al. [13] seems to be accidental, as the later was
determined by finding the best discrimination between
good and bad prognosis while we calculated the cut-off
value.
We did not find high levels of p53 to be an independent
predictor of prognosis. Previous research undertaken to
assess the prognostic value of p53-overexpression in
colorectalcarcinomashasrevealedcontradictoryresults
[20], [22]. Direct comparison between these results is
difficult due to the use of different monoclonal and poly-
clonalantibodies,variousmethodsinpreparingsamples,
a general lack of consensus in the interpretation of
staining results and other investigator-related factors
[23]. Interestingly, Bosari et al. Flamini et al. and Sun et
al. described a strong correlation between immunohisto-
chemicallydetectedp53-overexpressioninthecytoplasm
of malignant cells and shorter overall-survival, with nu-
cleardetectionnotbeingrelatedtoworseprognosis[24],
[25], [26]. Some studies have shown that wild-type p53
is restricted to the nucleus, whereas the mutant form
interactswiththecytoplasmaticheat-shock-proteinfamily
and can even be found in both cellular compartments
[6].Thismaybeofinterestinmeasuringp53byimmuno-
luminometric assay, as it detects cytoplasmatic and not
nuclear phosphoprotein.
Our investigation revealed that p53-overexpression, as
measured by a luminometric immunoassay, is not a
useful predictor of prognosis in patients with colorectal
adenocarcinomas. At present, molecular techniques are
still not suitable for routine clinical application. However,
detectionofp53-proteinhasbeenproposedasanindirect
methodofscreeningtumorsformutationswithinthep53-
gene. One of the major advantages of this procedure, in
contrast to genetic analysis, is that a statement on the
protein's functional status can be made [27].
The limit of immunohistochemistry in p53-protein detec-
tion is its semiquantitative approach which is surpassed
by quantitative immunoluminometry. The latter is crucial
incomparisonwiththeanalyticaldeterminationofserum
p53-antibodies. Suppiah et al. found that anti-p53
autoantibody sero-positivity did not influence the overall
ordisease-specificsurvivalandwasnotrelatedtoclinical
parameters of colorectal cancer, matching with our re-
sults. According to our findings, UICC Stage III/IV is the
onlyindependentprognosticfactorinoverallanddisease-
free survival [28], [29]. To our knowledge, no study has
examinedthecorrelationbetweenserump53-antibodies
and quantitative immunoluminometric p53 in cytosols.
Still TNM classification seems to be the best predictor of
outcome, although no distinction between good and un-
favourable prognosis within the groups can be made. To
date, the numerous and complex ways by which the
phosphoproteinregulatescellgrowtharenotexhaustively
understood. Furthermore, research on p53 is necessary
to elucidate its mechanisms in order to allow a better in-
terpretation of clinical studies with long-term follow-up
about the protein's possible role as a prognostic factor.
Sofar,insufficientevidenceexiststorecommendroutine
use of p53 in colorectal adenocarcinoma [30].
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Immunohistochemical detection of p53 depends on sev-
eral investigator-related factors which can be eliminated
by the objective quantitative measurement of immuno-
luminometry. No study has examined the quantitative
p53-expression in the cytosol of colorectal carcinoma
before. In our study no correlation could be found
between cytosolic p53-expression and various clinico-
pathological parameters. Low p53-expression, however,
has a slightly better prognosis in terms of disease-free
andoverallsurvivalbutthisisnotstatisticallysignificant.
Expressionofp53remainsanunclearprognosticparam-
eter in colorectal carcinoma. As soon as the exact
mechanisms of p53 in tumorigenesis are known, inter-
pretation of clinical studies with long-term follow-up for
p53 as a potential prognostic factor are then possible.
The relationship between serum p53-antibodies and
quantitative immunoluminometric p53 in cytosols of
tumors could help to understand these mechanisms.
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